Bankrupt Gritstone bio in funding talks
https://seekingalpha.com/news/4166430-bankrupt-gritstone-bio-funding-talk?source=feed_sector_healthcare
Oct 16, 2024 - Gritstone Bio, which filed for Chapter 11 bankruptcy, is in talks for funding to keep the company running. Read more here.
0
Adicet Bio gets FDA clearance of IND amendment for stiff person syndrome treatment
https://seekingalpha.com/news/4165591-adicet-bio-gets-fda-clearance-of-ind-amendment-for-stiff-person-syndrome-treatment?source=feed_sector_healthcare
Oct 16, 2024 - Adicet Bio receives FDA clearance to evaluate ADI-001 in autoimmune diseases.
0
Annovis Bio up 5% as FDA clears phase 3 buntanetap program for Alzheimer's
https://seekingalpha.com/news/4161832-annovis-bio-up-5-fda-clears-phase-3-buntanetap-program-alzheime?source=feed_sector_healthcare
Oct 15, 2024 - Annovis Bio (ANVS) receives FDA approval for phase 3 program of Alzheimer's drug buntanetap. Read more here.
0
Upstream Bio stock rallies 32% following upsized $255M IPO
https://seekingalpha.com/news/4157979-upstream-bio-stock-rallies-following-upsized-255m-ipo?source=feed_sector_healthcare
Oct 11, 2024 - Upstream Bio (UPB) shares rallied 32% Friday following the asthma drug developer’s $255M upsized initial public offering. Read more here.
0
Tourmaline Bio stock slides 7% amid news of CMO's departure
https://seekingalpha.com/news/4157917-tourmaline-bio-stock-slides-amid-news-of-cmo-departure?source=feed_sector_healthcare
Oct 11, 2024 - Tourmaline Bio (TRML) shares were down 7% early Friday, the day after the company disclosed that its chief medical officer was leaving the company. Read more here.
0
Upstream Bio, CeriBell, CAMP4 set terms for proposed IPOs
https://seekingalpha.com/news/4157126-upstream-bio-ceribell-camp4-set-terms-for-proposed-ipos?source=feed_sector_healthcare
Oct 08, 2024 - Upstream Bio (UPB), CeriBell (CBLL) and CAMP4 Therapeutics (CAMP) have set terms for their proposed initial public offerings. Read more here.
0
MBX Bio drops despite bullish views on Street
https://seekingalpha.com/news/4157091-mbx-bio-stock-drops-despite-bullish-initiations-?source=feed_sector_healthcare
Oct 08, 2024 - BX Biosciences (MBX) stock drops even as several Wall Street firms launched its coverage with buy recommendations. Read more here.
0
Annovis Bio: Progress With Buntanetap In Parkinson's Disease, But Cash Runway Concerns Loom
https://seekingalpha.com/article/4723615-annovis-bio-progress-buntanetap-parkinsons-disease-cash-runway-concerns-loom?source=feed_all_articles
Sep 26, 2024 - Annovis Bio saw promising results for Buntanetap in treating Alzheimer's and Parkinson's, but short cash runway prompts a hold rating. Read more on ANVS here.
0
Emergent Bio gains after U.S. govt. order for smallpox therapy
https://seekingalpha.com/news/4153867-emergent-bio-stock-gains-us-govt-order?source=feed_sector_healthcare
Sep 26, 2024 - Emergent BioSolutions (EBS) stock gains as the company receives $67.4M order from U.S. to supply its smallpox therapy, Tembexa. Read more here.
0
Upstream Bio Pursues $100 Million IPO Plan With Encouraging Trial Results
https://seekingalpha.com/article/4723271-upstream-bio-pursues-100-million-ipo-plan-with-encouraging-trial-results?source=feed_tag_ipo_analysis
Sep 25, 2024 - Upstream Bio plans to IPO to advance its Phase 2 drug candidate, verekitug, for severe asthma and chronic rhinosinusitis. Click here to read an analysis of UPB stock now.
0